Alrubicin 10mg Injection

About

Alrubicin 10mg Injection is a lower-dose formulation of an anthracycline chemotherapeutic agent, administered intravenously for the treatment of various malignancies. This cytotoxic drug functions by intercalating into DNA, inhibiting topoisomerase II, and generating reactive oxygen species, leading to DNA damage and subsequent programmed cell death in rapidly proliferating cancer cells. While the 10mg dose is lower, it retains the potent anti-tumor activity characteristic of anthracyclines and is often used in specific regimens, for dose titration, or in combination therapies where a lower individual dose contributes to the overall treatment strategy. Alrubicin is effective against a range of solid tumors and hematological cancers, including breast cancer, lymphomas, and leukemias. Due to its known risk of dose-dependent cardiotoxicity, careful assessment of cardiac function is essential before and during treatment to manage this significant adverse effect and ensure patient safety.

Uses

• Treatment of breast cancer.
• Management of lymphomas and leukemias.
• Therapy for soft tissue sarcomas.
• Adjuvant therapy in various solid tumors.

Directions For Use

Administer intravenously under the supervision of a qualified oncologist. Dosage and administration schedule are determined by the specific cancer type, patient's body surface area, and overall treatment plan.

Benefits

• Highly effective against a wide range of cancers.
• Induces significant tumor regression.
• Often used as a foundational agent in chemotherapy.
• Available in injectable form for systemic delivery.
• Can be combined with other agents for enhanced efficacy.
• Proven track record in improving survival rates.

Side Effects

• Myelosuppression (low blood counts).
• Cardiotoxicity (heart damage).
• Nausea and vomiting.
• Alopecia (hair loss).
• Mucositis (inflammation of mucous membranes).
• Red discoloration of urine.
• Fatigue.
• Injection site reactions.
• Diarrhea or constipation.
• Anorexia (loss of appetite).
• Hyperpigmentation of skin/nails.
• Secondary malignancies (rare, long-term).

Safety Measures

• Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver toxicity or gastrointestinal side effects associated with chemotherapy.
• Pregnancy - Contraindicated; Alrubicin is highly teratogenic and can cause severe fetal harm. Effective contraception is mandatory during and after treatment.
• Breastfeeding - Contraindicated; Alrubicin is excreted in breast milk and can cause serious adverse effects in the infant. Discontinue breastfeeding immediately.
• Liver - Use with extreme caution in patients with hepatic impairment; significant dose reductions are required, and liver function must be closely monitored due to altered metabolism.
• Kidney - Administer with caution in patients with renal impairment; dose adjustments may be necessary, and kidney function should be monitored.
• Lung - Monitor for signs of pulmonary toxicity (e.g., pneumonitis), especially in patients with pre-existing lung conditions or those receiving radiation to the chest.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.